At least 468 individual genes have been manipulated by molecular methods to study their
effects on the initiation, promotion, and progression of atherosclerosis. Most clinicians and …

This review of the role of platelets in atherothrombosis illuminates the surprisingly numerous
activities of these tiny, anucleate cells and stresses their participation in the inflammatory …

Background Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an
increased risk of thrombotic events, but only limited long-term data have been available for …

Platelets are central to inflammation-related manifestations of cardiovascular diseases
(CVD) such as atherosclerosis. Platelet-activating factor (PAF), thrombin, thromboxane A 2 …

Clinical trial data have prompted questions about the degree to which patients and their
physicians should consider an increased risk of cardiovascular or cerebrovascular events …

The prostanoids are a family of lipid mediators generated by the action of cyclooxygenase
on a 20-carbon unsaturated fatty acid, arachidonic acid. Prostanoids are generated widely in …

Prostaglandins, leukotrienes, platelet-activating factor, lysophosphatidic acid, sphingosine 1-
phosphate, and endocannabinoids, collectively referred to as lipid mediators, play pivotal …

Aspirin and P2Y12 antagonists are commonly used anti‐platelet agents. Aspirin produces its
effects through inhibition of thromboxane A2 (TXA2) production, while P2Y12 antagonists …

In mammalian cells, eicosanoid biosynthesis is usually initiated by the activation of
phospholipase A2 and the release of arachidonic acid (AA) from membrane phospholipids …

The early and high-throughput application of assays for non-genetic toxicity is of great
interest to the pharmaceutical industry, although few systems have been validated as being …